Sep-29-20 Resumed
JP Morgan
Underweight
$8
Aug-25-20 Downgrade
Goldman
Buy → Neutral
$25 → $10
Jun-27-19 Initiated
Goldman
Buy
$48
May-24-19 Initiated
Needham
Buy
$50
Jul-23-18 Initiated
JP Morgan
Neutral
$34
Jul-23-18 Initiated
Goldman
Neutral
$32
Jan-15-21 12:45PM
12:00PM
11:30AM
11:00AM
11:00AM
06:12AM
Jan-14-21 10:00PM
05:20PM
04:00PM
02:43PM
12:00PM
12:00PM
11:00AM
Jan-13-21 08:00PM
05:27PM
04:00PM
04:00PM
02:33PM
01:00PM
11:45AM
11:00AM
11:00AM
06:30AM
12:00AM
Jan-12-21 02:00PM
01:00PM
12:50PM
12:30PM
12:05PM
11:30AM
11:00AM
Jan-11-21 03:00PM
02:15PM
01:00PM
12:30PM
12:00PM
11:15AM
10:57AM
09:33AM
09:05AM
08:00AM
08:00AM
Jan-10-21 10:25AM
Jan-09-21 07:15PM
Jan-08-21 04:00PM
02:35PM
01:31PM
01:15PM
12:05PM
12:00PM
11:15AM
10:40AM
10:00AM
Jan-07-21 10:28PM
10:19PM
09:00PM
08:29PM
06:59PM
06:11PM
05:00PM
03:36PM
11:00AM
11:00AM
Jan-06-21 11:30PM
11:30PM
06:30PM
04:30PM
Dec-16-20 03:51PM
Dec-09-20 07:23AM
Dec-08-20 04:05PM
Dec-07-20 04:05PM
Dec-05-20 10:23AM
Dec-01-20 09:22PM
Nov-30-20 08:33PM
Nov-24-20 08:33PM
Nov-20-20 08:44PM
Nov-15-20 11:02AM
Nov-11-20 08:19PM
Nov-09-20 07:00PM
04:05PM
Nov-07-20 09:22PM
Nov-05-20 08:55PM
Nov-04-20 08:30PM
Nov-01-20 10:52AM
Oct-30-20 08:30PM
Oct-29-20 06:58PM
04:35PM
07:30AM
Oct-28-20 04:00PM
Oct-09-20 11:00AM
Sep-29-20 08:00PM
08:56AM
Sep-11-20 02:08PM
Sep-10-20 12:25PM
Sep-08-20 02:55PM
Sep-04-20 05:30PM
Sep-02-20 12:55PM
Sep-01-20 11:45PM
Aug-31-20 08:52PM
09:12AM
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KLAERNER GERRIT President and CEO Jan 14 Sale 7.18 1,655 11,883 507,993 Jan 15 04:32 PM KLAERNER GERRIT President and CEO Jan 13 Sale 7.41 15,035 111,409 509,648 Jan 15 04:32 PM KLAERNER GERRIT President and CEO Jan 12 Sale 7.65 9,821 75,131 524,683 Jan 13 04:38 PM KLAERNER GERRIT President and CEO Jan 11 Sale 7.49 21,489 160,953 534,504 Jan 12 04:31 PM COUFAL SANDRA I Director Dec 14 Sale 7.90 50,000 395,000 172,609 Dec 15 05:46 PM McKague Robert EVP, General Counsel Dec 11 Buy 7.62 10,000 76,200 10,000 Dec 23 05:34 PM Parker Geoffrey M. CFO and EVP Dec 10 Buy 6.78 15,000 101,700 40,000 Dec 10 07:46 PM KLAERNER GERRIT President and CEO Jul 15 Sale 26.33 4,000 105,320 25,323 Jul 16 07:30 PM KLAERNER GERRIT President and CEO Jul 01 Sale 27.15 4,000 108,600 547,321 Jul 02 04:57 PM KLAERNER GERRIT President and CEO Jun 15 Sale 25.97 4,000 103,869 29,323 Jun 16 08:14 PM KLAERNER GERRIT President and CEO Jun 01 Sale 26.23 4,000 104,920 551,321 Jun 03 04:39 PM KLAERNER GERRIT President and CEO May 15 Sale 31.56 4,000 126,220 33,323 May 19 07:07 PM Parker Geoffrey M. Chief Fin. Officer and EVP May 12 Buy 30.91 2,742 84,766 95,000 May 12 08:45 PM Parker Geoffrey M. Chief Fin. Officer and EVP May 11 Buy 30.02 32,258 968,437 92,258 May 12 08:45 PM Otto Dawn Parsell EVP, Clinical Development May 08 Option Exercise 3.03 3,000 9,099 1,692 May 12 08:38 PM Otto Dawn Parsell EVP, Clinical Development May 08 Sale 31.98 3,000 95,940 255 May 12 08:38 PM Otto Dawn Parsell EVP, Clinical Development May 05 Option Exercise 1.94 1,250 2,421 1,053 May 07 05:33 PM Otto Dawn Parsell EVP, Clinical Development May 05 Sale 30.14 1,250 37,680 255 May 07 05:33 PM KLAERNER GERRIT President and CEO May 01 Sale 27.98 4,000 111,906 555,321 May 04 05:34 PM Otto Dawn Parsell EVP, Clinical Development Apr 29 Option Exercise 2.82 3,000 8,450 1,999 Apr 30 04:33 PM Otto Dawn Parsell EVP, Clinical Development Apr 29 Sale 31.98 3,000 95,940 255 Apr 30 04:33 PM Otto Dawn Parsell EVP, Clinical Development Apr 28 Option Exercise 1.68 1,250 2,100 1,505 Apr 30 04:33 PM Otto Dawn Parsell EVP, Clinical Development Apr 28 Sale 29.98 1,250 37,475 255 Apr 30 04:33 PM KLAERNER GERRIT President and CEO Apr 15 Sale 27.47 4,000 109,891 37,323 Apr 16 08:05 PM KLAERNER GERRIT President and CEO Apr 06 Sale 24.22 4,000 96,880 559,321 Apr 08 04:34 PM KLAERNER GERRIT President and CEO Mar 16 Sale 23.91 4,000 95,640 41,323 Mar 18 04:09 PM Parker Geoffrey M. Chief Fin. Officer and EVP Mar 10 Buy 29.46 5,000 147,300 55,000 Mar 11 05:10 PM HEJLEK EDWARD J EVP, General Counsel & Secy. Mar 02 Option Exercise 0.96 10,000 9,600 28,953 Mar 04 07:36 PM Otto Dawn Parsell EVP, Clinical Development Mar 02 Option Exercise 2.48 4,250 10,550 3,249 Mar 04 07:38 PM HEJLEK EDWARD J EVP, General Counsel & Secy. Mar 02 Sale 31.66 10,000 316,616 19,153 Mar 04 07:36 PM KLAERNER GERRIT President and CEO Mar 02 Sale 31.53 4,000 126,120 563,321 Mar 04 07:33 PM Otto Dawn Parsell EVP, Clinical Development Mar 02 Sale 31.84 4,250 135,316 255 Mar 04 07:38 PM KLAERNER GERRIT President and CEO Feb 18 Sale 36.10 4,000 144,400 45,323 Feb 20 04:42 PM Stahl Wilhelm Chief Tech Officer & Sr. VP Feb 05 Option Exercise 1.68 500 840 15,306 Feb 06 05:07 PM Stahl Wilhelm Chief Tech Officer & Sr. VP Feb 05 Sale 38.91 500 19,455 14,806 Feb 06 05:07 PM HEJLEK EDWARD J SVP, General Counsel & Secy. Feb 03 Option Exercise 0.96 10,000 9,600 27,022 Feb 05 09:29 PM Otto Dawn Parsell Sr VP, Clinical Development Feb 03 Option Exercise 2.48 4,250 10,550 3,249 Feb 05 09:31 PM Otto Dawn Parsell Sr VP, Clinical Development Feb 03 Sale 36.86 4,250 156,668 255 Feb 05 09:31 PM HEJLEK EDWARD J SVP, General Counsel & Secy. Feb 03 Sale 36.42 10,000 364,169 19,153 Feb 05 09:29 PM KLAERNER GERRIT President and CEO Feb 03 Sale 36.33 4,000 145,330 567,321 Feb 05 09:27 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite